Mylan (MYL) Receives FDA Approval for Carvedilol Tablets
More News related to GSK
- Piper Jaffray Downgrades Phase Forward (PFWD) to Neutral; Lack of Near-Term Catalysts
- Phase Forward (PFWD) Signs Multi-Yr, Multi-Million Dollar Contract with GlaxoSmithKline (GSK)
- Launch of Targeted Agents and Increased Use of Maintenance Therapy Will Drive the Non-Small-Cell Lung Cancer Drug Market to Nearly Triple to Almost $10 Billion in 2018
- Society of Hispanic Professional Engineers Elects New National Board With Raytheon's Manny Hernandez as President
- Morning Movers 6/17: MERX, CYTR, SVNT, MIPI, TSTR Higher; ETFC, CTIC, AIB Lower
More News related to MYL
- PARI LC Plus and PRONEB Ultra Used in Two Perforomist Studies on Improving COPD Therapies
- Mylan (MYL) Announces Exclusive Collaboration with Biocon to Enter Global Generic Biologics Market
- Mylan Announces Strategic Collaboration with Biocon to Enter the Global Generic Biologics Market
- FTN Equity Starts Mylan Labs (MYL) at Neutral
- Mylan (MYL) Receives FDA Approval for ANDA for Temazepam Capsules USP, 22.5 mg
Mylan Laboratories Inc. (NYSE: MYL) received final approval from the FDA for its Abbreviated New Drug Application for Carvedilol Tablets, 3.125 mg, 6.25 mg, 12.5 mg and 25 mg.
Carvedilol Tablets are the generic version of GlaxoSmithKline's Coreg Tablets.
Related Categories
Corporate NewsStocks Mentioned
-7.34Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
